Physician profile
Peter Bosco
NPI 1992725683
$3,279.57
in general payments reported to CMS, 2019-2025
31 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $127 · 2021: $336 · 2022: $464 · 2023: $724 · 2024: $921 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $467.42 | 2019-2025 | |
| Janssen Biotech, INC. | $344.60 | 2019-2024 | Erleada, Akeega, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $312.77 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $255.71 | 2023-2024 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $248.27 | 2019-2025 | Xtandi, Veozah |
| Merck Sharp & Dohme LLC | $230.53 | 2019-2024 | Lynparza, Keytruda, Welireg |
| Myriad Genetic Laboratories, INC. | $156.99 | 2021-2024 | Prolaris |
| Progenics Pharmaceuticals, INC. | $132.60 | 2023 | Pylarify |
| Innovation Technologies INC | $114.23 | 2023 | Irrisept |
| Endo Pharmaceuticals INC. | $94.11 | 2020-2023 | Aveed, Xiaflex |
| Urogen Pharma, INC. | $85.30 | 2024-2025 | |
| Accord Healthcare, INC. | $82.54 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $75.59 | 2024-2025 | Adstiladrin |
| Tolmar, INC. | $71.23 | 2023-2024 | |
| Axonics, INC. | $61.43 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $61.28 | 2024 | |
| Sun Pharmaceutical Industries INC. | $50.72 | 2023 | Yonsa |
| Convatec INC. | $45.35 | 2024 | |
| Dentsply Ih INC. | $43.99 | 2021 | |
| Urovant Sciences INC | $40.91 | 2021-2022 | |
| Abbvie INC. | $40.41 | 2024-2025 | |
| 180 Medical, INC. | $36.88 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $35.73 | 2022 | |
| Allergan, INC. | $32.10 | 2019-2021 | |
| Endo USA, INC. | $27.80 | 2025 | Xiaflex, Aveed |
| Myovant Sciences INC. | $26.68 | 2022 | |
| Halozyme INC | $24.63 | 2023 | |
| Boston Scientific Corporation | $22.37 | 2021 | |
| Procept Biorobotics Corporation | $20.40 | 2024 | Aquabeam System |
| Olympus America INC. | $19.47 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bosco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.